$PVCT: Craig Redux

Craig presented in town to about 40 biotech and life sciences industry folks, together with a handful of investment management people, this week. I learned several interesting things, such as...

Craig's murine work on bladder cancer appears to have successfully demonstrated what he had intended with treated and untreated lesions.

He also indicated success with the bystander for pancreatic cancer in, I presume, murine models.

The number of Big Pharma in due diligence with Provectus has increased to at least 4 companies.